Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (DE:82P)
FRANKFURT:82P
RESEARCH TOOLSreports
Holding DE:82P?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
€0.76Last Year’s EPS
€0.85Same Quarter Last Year
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: 12.35%
|Next Earnings Date:Feb 27, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a cautiously optimistic outlook with significant advancements in market access, gene therapy development, and financial stability. However, challenges remain, particularly around patent litigation and flat ZILRETTA sales.Company Guidance
During the third-quarter 2024 earnings call, Pacira BioSciences, Inc. provided guidance that reaffirmed their full-year projections, expecting total revenue between $680 million and $705 million. The company reported strong third-quarter sales for its leading products with EXPAREL reaching $132 million, ZILRETTA at $28.4 million, and iovera° at $5.7 million. Pacira emphasized its strategic focus on expanding market access and utilization of EXPAREL, anticipating an impact from the NOPAIN reimbursement policy set to commence in 2025. The company is also investing in its pipeline, with promising data from the PCRX-201 program for osteoarthritis. Pacira's non-GAAP gross margins for the quarter were 78%, and they expect full-year margins to be between 74% and 76%. Non-GAAP R&D expenses are projected to range from $70 million to $80 million, while SG&A expenses are estimated at $245 million to $265 million. The company remains confident in its position for sustained growth and leadership in non-opioid pain management.EXPAREL Expansion and J-code Introduction
EXPAREL will have its own product-specific J-code starting January 2025, expected to streamline reimbursement and expand access across different sites of care.
Strong Financial Position
Pacira ended Q3 with more than $450 million in cash and investments, demonstrating strong financial footing and the ability to support long-term growth strategies.
Positive Progress in Gene Therapy
PCRX-201, the novel gene therapy for osteoarthritis, showed promising results in a Phase I trial and has received the FDA's RMAT designation.
Partnerships and Market Access
New partnership with Vizient covers 30% of EXPAREL market procedures, with a third GPO partnership expected to cover another 20% of the market soon.
Financial Metrics
Achieved significant adjusted EBITDA of $54.7 million and a non-GAAP gross margin of 78%.
---
DE:82P Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:82P Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | €16.20 | €16.40 | +1.23% |
| Jul 30, 2024 | €18.60 | €20.00 | +7.53% |
| May 07, 2024 | €24.60 | €26.60 | +8.13% |
| Feb 29, 2024 | €27.20 | €27.40 | +0.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pacira Pharmaceuticals (DE:82P) report earnings?
Pacira Pharmaceuticals (DE:82P) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Pacira Pharmaceuticals (DE:82P) earnings time?
Pacira Pharmaceuticals (DE:82P) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Pacira Pharmaceuticals stock?
The P/E ratio of Pacira Pharmaceuticals is N/A.
What is DE:82P EPS forecast?
DE:82P EPS forecast for the fiscal quarter 2024 (Q4) is €0.76.
---